This is a StreetInsider.com Premium Only Page

(INMB) – StreetInsider.com Reports

Mar 5, 2024 08:05 AM INmune Bio (INMB) Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro

Jan 30, 2024 08:00 AM INmune Bio (INMB) Reports FDA Removed Clinical Hold for Alzheimer’s Disease Program

Dec 18, 2023 04:01 PM INmune Bio (INMB) Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the FDA

Nov 29, 2023 08:06 AM INmune Bio (INMB) Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster

Nov 27, 2023 08:03 AM INmune Bio (INMB) Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer’s Disease

Nov 15, 2023 09:01 AM INmune Bio (INMB) Expands Phase II Clinical Trial for Alzheimer’s Disease in Europe

Nov 1, 2023 04:12 PM INmune Bio, Inc. (INMB) Misses Q3 EPS by 8c

Oct 17, 2023 08:00 AM INmune Bio (INMB) Presents New Biomarker and Feasibility Data from Phase 1b Study

Sep 5, 2023 08:02 AM INmune Bio (INMB) Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease

Aug 7, 2023 04:42 PM INmune Bio, Inc. (INMB) Tops Q2 EPS by 4c

Jun 1, 2023 06:33 AM Baird Starts INmune Bio Inc. (INMB) at Outperform; XPro has promise in Alzheimer's

May 8, 2023 08:04 AM INmune Bio (INMB) Announces FDA Clearance of IND Application for INKmune, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

May 3, 2023 04:51 PM INmune Bio, Inc. (INMB) Tops Q1 EPS by 18c

Apr 3, 2023 09:00 AM INmune Bio (INMB) Announces Submission of IND Application for INKmune to FDA for Treatment of Metastatic Castration-Resistant Prostate Cancer

Feb 8, 2023 08:46 AM INmune Bio (INMB) Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom

Jan 25, 2023 07:45 AM INmune Bio (INMB) Reports Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy

Dec 6, 2022 04:02 PM INmune Bio (INMB) Reports Combination Therapy with INB03 Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer

Nov 14, 2022 09:00 AM INmune Bio (INMB) Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease

Jun 16, 2022 08:04 AM INmune Bio (INMB) Reports Data on Combination Therapy with INB03 on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer

May 24, 2022 09:14 AM Pre-Open Stock Movers 05/24: Snap's Warning Sends Tech Stocks Reeling; Insulet Gains on Deal Talk (more...)

May 24, 2022 07:31 AM B.Riley Downgrades INmune Bio Inc. (INMB) to Neutral

May 24, 2022 06:56 AM INmune Bio Inc. (INMB) PT Lowered to $14 at BTIG

May 23, 2022 05:54 PM After-Hours Stock Movers 05/23: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results (more...)

May 23, 2022 04:04 PM INmune Bio (INMB) Declines 17% After Phase 2 Alzheimer’s Drug Placed Clinical Hold

May 23, 2022 04:00 PM INmune Bio (INMB) Announces FDA Request for Additional Manufacturing Information for XPro1595

May 10, 2022 08:03 AM INmune Bio (INMB) Reports Data Demonstrating XPro Promotes Remyelination in Gray Matter

Apr 13, 2022 04:01 PM INmune Bio (INMB) Dosed First Patient in Phase 2 Trail of XPro1595

Mar 3, 2022 04:00 PM INmune Bio (INMB) Reports Q4, Provides Business Update

Jan 24, 2022 07:48 AM INmune Bio Inc. (INMB) PT Lowered to $20 at B.Riley

Sep 7, 2021 07:32 AM INmune Bio Inc. (INMB) PT Raised to $32 at B.Riley

Sep 2, 2021 09:16 AM Pre-Open Stock Movers 09/02: (SIG) (INMB) (NKLA) Higher; (METX) (ASMB) (AEO) Lower (more...)

Sep 1, 2021 06:04 PM After-Hours Stock Movers 09/01: (INMB) (NCNO) (SMTC) Higher; (METX) (CHWY) (VEEV) Lower (more...)

Sep 1, 2021 04:07 PM INmune Bio (INMB) XPro Show Reduction in CSF Phospho-Tau and Evidence of Remyelination in Alzheimer's Patients

Jul 22, 2021 11:55 AM INmune Bio (INMB) acquires LUMICKS' z-Movi Cell Avidity Analyzer to accelerate the development of its NK cell platform for cancer treatments

Jul 14, 2021 09:02 AM INmune Bio (INMB) Announces 1.8M Direct Share Offering at $22/sh

Jul 14, 2021 07:32 AM INmune Bio Inc. (INMB) PT Raised to $34 at B.Riley

Jun 14, 2021 04:04 PM INmune Bio, Inc. (NASDAQ: INMB) Announced $15M Credit Facility to Reduce Further Dilution

Apr 30, 2021 06:43 AM Companies with NDRs 4/30

Apr 27, 2021 07:03 AM Companies with NDRs 4/27

Apr 21, 2021 03:49 AM B.Riley Starts INmune Bio Inc. (INMB) at Buy

Jan 29, 2021 05:41 AM INmune Bio Inc. (INMB) PT Raised to $31 at BTIG

Jan 22, 2021 07:58 AM INmune Bio Inc. (INMB) PT Raised to $32 at Maxim Group

Jan 21, 2021 09:08 AM Pre-Open Stock Movers 1/21: (INMB) (OCX) (VIR) Higher; (MARA) (RIOT) (MAXR) Lower (more...)

Jan 21, 2021 07:04 AM INmune Bio (INMB) Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial

Oct 5, 2020 09:08 AM INmune Bio (INMB) Presents Preliminary Phase I Data at 21st International Conference on Alzheimer's Drug Discovery

Sep 16, 2020 07:04 AM INmune Bio (INMB) Secures $2.9M NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595

Sep 3, 2020 09:04 AM INmune Bio (INMB) Announces Issuance of Patent from U.S. Patent & Trademark Office Covering INKmune Therapy

Sep 1, 2020 09:09 AM INmune Bio (INMB) Reports FDA Acceptance of IND Application to Evaluate Quellor in Blinded Randomized Phase 2 Trial for Immune Mediated Complications in COVID-19 Patients

Sep 1, 2020 05:20 AM BTIG Starts INmune Bio Inc. (INMB) at Buy

Aug 13, 2020 09:02 AM INmune Bio (INMB) Announces European Patent Granted Covering INmune Bio's XPro1595